3-dimensional large capacity cell encapsulation device assembly

Patent metadata

Field	Value
Publication number	US-9526880-B2
Application number	US-201414201630-A
Country	US
Kind code	B2
Filing date	Mar 7, 2014
Priority date	Mar 7, 2013
Publication date	Dec 27, 2016
Grant date	Dec 27, 2016

Abstract

Disclosed herein are implantable 3-dimensional large capacity device assemblies, specifically, large capacity device assemblies for encapsulating pancreatic progenitor cells for treatment of diabetes.

First claim

What is claimed is:

1. A cell encapsulating assembly, said assembly comprising at least two cell chambers and a cell-free region along the longest axis separating the cell chambers, wherein the cell-free region is bent 5 to 175 degrees.

2. The assembly of claim 1 , wherein the assembly comprises a semi-permeable membrane.

3. The assembly of claim 1 , wherein the assembly comprises at least three, four, five, six, seven, eight or more cell chambers.

4. The assembly of claim 1 , further comprising at least one loading port.

5. The assembly of claim 1 , further comprising definitive endoderm-lineage cells.

6. The assembly of claim 1 , further comprising human immature beta cells.

7. The assembly of claim 1 , further comprising a cell chamber matrix having a plurality of interconnected cavities or pores to disperse the living cells and to improve oxygen distribution inside the cell chamber.

8. The assembly of claim 7 , wherein the interconnected cavities have different cavity dimensions.

9. The assembly of claim 7 , wherein the matrix is polydimethylsiloxane (PDMS), polydimethylsiloxane mono acrylate, and polydimethylsiloxane monomethacrylate.

10. The assembly of claim 7 , wherein the matrix is a silicone elastomer.

11. The assembly of claim 7 , wherein the matrix is a polydimethylsiloxane (PDMS).

12. The assembly of claim 1 , wherein the cell chambers are separated by about 20 degrees.

13. The assembly of claim 1 , wherein the cell chambers are separated by about 40 degrees.

14. A encapsulating assembly, said assembly comprising at least two cell chambers, a cell-free region along the longest axis separating the cell chambers, wherein the cell-free region is bent 5 to 175 degrees, further comprising human endocrine precursor cells.

15. The assembly of claim 14 , further comprising human pancreatic and duodenal homeobox gene 1 (PDX1)-positive pancreatic progenitor cells.

16. The assembly of claim 1 , further comprising a partition seal within the cell chamber.

17. A cell encapsulating assembly, said assembly comprising at least two cell chambers and a cell-free region along the longest axis separating the cell chambers, wherein the cell-free region is bent 5 to 175 degrees and further comprising pancreatic and duodenal homeobox gene 1 (PDX1)-positive pancreatic progenitor cells.

Assignees

• Viacyte Inc

Inventors

• So Vincent
• Martinson Laura
• Green Chad
• Scott Michael
• Zamarripa Mario

Classifications

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61M2202/09

  Body tissue · CPC title

• A61M31/002 Primary

  Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time (artificial gland structures or devices A61F2/022; intra-uterine contraceptive devices A61F6/14; tampons for introducing into the vagina A61F13/20, A61L15/00; suppositories or bougies for intra-vaginal or intra-uterine application A61K9/02; physical forms of medicinal preparations for sustained or differential drug release A61K9/20, A61K9/50) · CPC title

• A61F2/022 Primary

  Artificial gland structures using bioreactors (hemodialysis A61M1/16; hemofiltration A61M1/34; other extracorporeal blood treatment A61M1/36) · CPC title

• A61M2205/04

  implanted · CPC title